CRTE7A2-01 TCR-T Cell not checked

Corregene Biotechnology Co., Ltd · CRTE7A2

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell”In the company’s words, NCT06358053 on ClinicalTrials.gov
Tested for
Cervical Cancer, Anal Cancer, Head and Neck Cancers, Other Solid Tumors
Main trialPhase 1
“A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.”In the company’s words, NCT06358053 on ClinicalTrials.gov
Other names
CRTE7A2

Other drugs for Cervical Cancer

All 122 drugs for Cervical Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 31 Dec 2027 CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Phase 1Unknown Mar 2023 CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CRTE7A2-01 TCR-T Cell

Following is part of Solo: you see every change to CRTE7A2-01 TCR-T Cell the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in